CO2021007229A2 - Anticuerpo humanizado anti-receptor de igf-i - Google Patents

Anticuerpo humanizado anti-receptor de igf-i

Info

Publication number
CO2021007229A2
CO2021007229A2 CONC2021/0007229A CO2021007229A CO2021007229A2 CO 2021007229 A2 CO2021007229 A2 CO 2021007229A2 CO 2021007229 A CO2021007229 A CO 2021007229A CO 2021007229 A2 CO2021007229 A2 CO 2021007229A2
Authority
CO
Colombia
Prior art keywords
igf
receptor
humanized anti
receptor antibody
antibody
Prior art date
Application number
CONC2021/0007229A
Other languages
English (en)
Inventor
Kenichiro Takagi
Hiroshi Eguchi
Naoko Namiki
Akira Tanokura
Hirotsugu Kato
Satoshi Yamamura
Daisuke Ishikawa
Hirofumi Higuchi
Tomoyo Takeo
Masayo Ohori
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CO2021007229A2 publication Critical patent/CO2021007229A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Se proporciona un anticuerpo humanizado que aumenta la masa muscular por medio del receptor de IGF-I mientras que no disminuye el nivel de glucosa en sangre. Un anticuerpo humanizado anti-receptor de IGF-I o su fragmento o un derivado del mismo comprende secuencias de aminoácidos específicas, tales como SEQ ID NOs: 1 a 6 como cada secuencia de CDR, y puede unirse específicamente al dominio extracelular de un receptor de IGF-I.
CONC2021/0007229A 2018-12-03 2021-05-31 Anticuerpo humanizado anti-receptor de igf-i CO2021007229A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018226669 2018-12-03
PCT/JP2019/047050 WO2020116398A1 (ja) 2018-12-03 2019-12-02 抗ｉｇｆ－ｉ受容体ヒト化抗体

Publications (1)

Publication Number Publication Date
CO2021007229A2 true CO2021007229A2 (es) 2021-08-19

Family

ID=70974206

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0007229A CO2021007229A2 (es) 2018-12-03 2021-05-31 Anticuerpo humanizado anti-receptor de igf-i

Country Status (19)

Country Link
US (1) US20220033485A1 (es)
EP (1) EP3895732A4 (es)
JP (2) JP7246409B2 (es)
KR (1) KR20210088625A (es)
CN (1) CN113286612A (es)
AR (1) AR117673A1 (es)
AU (1) AU2019393487A1 (es)
BR (1) BR112021010479A2 (es)
CA (1) CA3120740A1 (es)
CL (1) CL2021001446A1 (es)
CO (1) CO2021007229A2 (es)
IL (1) IL283099A (es)
MA (1) MA54464A (es)
MX (1) MX2021006495A (es)
PH (1) PH12021551210A1 (es)
SG (1) SG11202105714UA (es)
TW (1) TW202039559A (es)
WO (1) WO2020116398A1 (es)
ZA (1) ZA202103350B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4159860A1 (en) * 2020-06-02 2023-04-05 Teijin Pharma Limited Anti-igf-1 receptor humanized antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302525A2 (hu) * 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
ES2388827T3 (es) 2008-04-03 2012-10-19 F. Hoffmann-La Roche Ag Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares
JP6096267B1 (ja) 2015-12-09 2017-03-15 上銀科技股▲分▼有限公司 ボールねじに用いる防塵ユニット
IL270971B1 (en) * 2017-05-30 2024-02-01 Teijin Pharma Ltd Antibody against the 1-IGF receptor

Also Published As

Publication number Publication date
US20220033485A1 (en) 2022-02-03
SG11202105714UA (en) 2021-06-29
WO2020116398A1 (ja) 2020-06-11
MA54464A (fr) 2021-10-20
CL2021001446A1 (es) 2022-01-14
EP3895732A4 (en) 2022-09-14
KR20210088625A (ko) 2021-07-14
ZA202103350B (en) 2022-08-31
TW202039559A (zh) 2020-11-01
JP2023011808A (ja) 2023-01-24
MX2021006495A (es) 2021-07-06
AU2019393487A1 (en) 2021-06-03
CN113286612A (zh) 2021-08-20
CA3120740A1 (en) 2020-06-11
AR117673A1 (es) 2021-08-25
IL283099A (en) 2021-06-30
JP7246409B2 (ja) 2023-03-27
PH12021551210A1 (en) 2021-11-08
JPWO2020116398A1 (ja) 2021-09-30
BR112021010479A2 (pt) 2021-11-16
EP3895732A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
AR110586A1 (es) Anticuerpo de receptor antitransferrina humana que penetra la barrera hematoencefálica
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
NZ610734A (en) Human antibodies to the glucagon receptor
CR10736A (es) Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon
PE20081546A1 (es) Antagonistas del dr6
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
DOP2010000294A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
MX2019015745A (es) Composiciones de anti-cgrp y uso de las mismas.
CO6460759A2 (es) Composiciones y métodos para aumentar el crecimiento muscular
EA201692460A1 (ru) Антитела, направленные на cd127
EA201001874A1 (ru) Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
PE20130815A1 (es) Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
CO2021007229A2 (es) Anticuerpo humanizado anti-receptor de igf-i
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
PE20141158A1 (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
PH12019502704A1 (en) Anti-igf-i receptor antibody
EA201201113A1 (ru) Способы и соединения для роста мышц
MX2021006457A (es) Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.
MX2021001592A (es) Nuevas construcciones de car que comprenden dominios de tnfr2.